postmenopausal heart health glp‑1

Study Compares GLP-1 Drugs on Their Benefits, Harms — Photo by Nataliya Vaitkevich on Pexels

Tirzepatide Cuts Weight 17% and Slashes Glp‑1 Heart Risk

In the STEP 1 trial, semaglutide led to an average 15% body-weight reduction, while also cutting major adverse cardiovascular events by 23%. These dual outcomes have shifted the conversation from pure weight loss to a broader cardiometabolic strategy, especially for postmenopausal women whose heart risk spikes after menopause. Below, I